Preliminary Safety, Pharmacokinetics, And Pharmacodynamics Of Duvelisib Plus Rituximab Or Obinutuzumab In Patients With Previously Untreated Cd20+Follicular Lymphoma

C. Casulo, E. Jacobsen,K. Van Eygen,H. E. Holmes, J. P. Lemmens, K. Allen, L. Steelman,V. Campbell,J. Nevejans,J. Pearlberg,A. Goy

Journal of Clinical Oncology（2016）

引用 4|浏览7

暂无评分

摘要

e19052Background: Duvelisib (IPI-145), an oral dual inhibitor of PI3K-δ and -γ, is being evaluated as an oral therapeutic for hematologic malignancies as a monotherapy or in combination with anti-C...

查看译文

关键词

lymphoma,obinutuzumab,rituximab,pharmacokinetics,untreated cd20+

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要